Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Other Non-Current Liabilities (2020 - 2025)

Lyell Immunopharma's Other Non-Current Liabilities history spans 6 years, with the latest figure at $2.7 million for Q3 2025.

  • For Q3 2025, Other Non-Current Liabilities fell 24.8% year-over-year to $2.7 million; the TTM value through Sep 2025 reached $2.7 million, down 24.8%, while the annual FY2024 figure was $3.3 million, 11.22% down from the prior year.
  • Other Non-Current Liabilities for Q3 2025 was $2.7 million at Lyell Immunopharma, down from $3.0 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $5.0 million in Q3 2021 and bottomed at $900000.0 in Q2 2021.
  • The 5-year median for Other Non-Current Liabilities is $3.7 million (2023), against an average of $3.6 million.
  • The largest annual shift saw Other Non-Current Liabilities skyrocketed 758.27% in 2021 before it decreased 24.8% in 2025.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $4.6 million in 2021, then fell by 9.92% to $4.1 million in 2022, then fell by 10.92% to $3.7 million in 2023, then fell by 11.22% to $3.3 million in 2024, then fell by 17.58% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Other Non-Current Liabilities are $2.7 million (Q3 2025), $3.0 million (Q2 2025), and $3.1 million (Q1 2025).